Regulatory9 min read
Bac Water Named in FDA Letters: Where to Buy Now
The FDA now lists bacteriostatic water itself as an unapproved drug when sold beside peptides. What that changes for diluent supply — and what it doesn't.
Peptide Regulatory News
FDA actions, public comments, compounding rules.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
State-by-state legal guides
Are peptides legal in your state? Updated for 2026.
Regulatory News
Regulatory10 min read
Copper Peptide Injections Hit NPR: What the Data Shows
NPR put GHK-Cu injections on national radio September 7. What the human record actually covers, what the February FDA panel decides, and how buyers verify.
Regulatory8 min read
FDA Warns 5 Peptide Vendors: Who's Named, What Changes
The FDA posted five peptide-vendor warning letters on September 1, citing retatrutide, tesamorelin and three more. Who was named and what it means.
Regulatory8 min read
Tirzepatide Wins FDA Heart-Risk Label: The Data
FDA cleared tirzepatide to cut major cardiac events in type 2 diabetes. What SURPASS-CVOT's 13,299 patients showed and what it changes for buyers.
Regulatory8 min read
Compounded GLP-1s: FDA Docket Closed, 3,901 Comments
The FDA's plan to bar 503B bulk compounding of semaglutide, tirzepatide and liraglutide drew 3,901 comments before the July 30 cutoff. What survives.
Regulatory7 min read
FDA Maps Generic Path for Semaglutide, Tirzepatide
The FDA published 17 revised generic-peptide guidances and pulled its 2021 synthetic-peptide rule. What it changes for GLP-1 pricing and access.
Regulatory6 min read
The $2.2B Race to Sell You Prescription BPC-157
Leerink pegs compounded peptides at a $2.2B telehealth market and Hims jumped 10% on the FDA vote. What the prescription route means for price and timing.
Regulatory5 min read
FDA's Next Peptide Panel: GHK-Cu, Melanotan, Dihexa
The FDA scheduled a second peptide panel by early 2027: GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF are next. What buyers should know.
Regulatory7 min read
FDA Peptide Panel: Members Sell BPC-157, TB-500
AP flagged FDA's peptide panel for members who sell BPC-157 and TB-500. Here's how the July 23-24 vote actually broke down — 6 of 7 recommended.
Regulatory5 min read
FDA Staff: No Compounding for BPC-157, TB-500, 5 More
FDA scientists recommend against adding BPC-157, TB-500, MOTS-c and 4 more to the compounding list before the July 23 vote. What it means for buyer access.
Regulatory5 min read
FDA Peptide Vote Results: What Buyers Need to Know
FDA panel backed BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon; DSIP rejected. What the results actually change for access — and what they don't.
Regulatory4 min read
FDA Hits 25 More Telehealth GLP-1 Sellers
FDA posted 25 new warning letters June 16 to telehealth firms over compounded semaglutide and tirzepatide claims. What it signals and what's still legal.
Regulatory5 min read
GLP-1s Now FDA-Approved for Fatty Liver Disease
Semaglutide and tirzepatide both FDA-approved for MASH. 63% resolution rate, fibrosis reversal in trials. What the data shows and sourcing options.
Regulatory5 min read
Ex-FDA Officials Push Back on RFK Peptide Reversal
Three former FDA officials say RFK Jr. mischaracterized their 2023 peptide-safety work. What the pushback means for buyers before the July 23 PCAC vote.
Regulatory8 min read
FDA Targets 503B GLP-1 Compounding: What Now
FDA proposed April 30 to bar 503B compounding of semaglutide, tirzepatide, and liraglutide. The comment window closed July 30. What survives the rule.
Regulatory4 min read
Orforglipron Approved: First Oral GLP-1 Pill
FDA approved orforglipron April 1 at $149/mo -- but compounded semaglutide still beats it on weight loss. Full cost and efficacy comparison inside.
Regulatory11 min read
14 Peptides Legal Again: FDA Reclassification Explained
RFK Jr. announced 14 of 19 banned peptides return to Category 1. Which ones, what it means for compounding, and 5 that stay restricted.
Regulatory8 min read
Dihexa: Off FDA Category 2, But Is It Legit?
Dihexa dropped off FDA Category 2 April 22. But the foundational research came from a company that paid $4M for misconduct. Here's the full picture.